Premium
Immunohistochemical expression of the estrogen receptor‐related antigen (ER‐D5) in human intracranial tumors
Author(s) -
Khalid Humayun,
Yasunaga Akio,
Kishikawa Masao,
Shibata Shobu
Publication year - 1995
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19950515)75:10<2571::aid-cncr2820751026>3.0.co;2-u
Subject(s) - immunohistochemistry , medicine , pathology , anaplastic astrocytoma , estrogen receptor , antigen , glioma , germ cell tumors , astrocytoma , cancer , cancer research , breast cancer , immunology , chemotherapy
Background . Expression of the estrogen receptor‐related antigen (ER‐D5) has been reported in some normal and neoplastic tissues. The authors evaluated the expression of ER‐D5 in 143 intracranial tumors of different histologic types. Methods . Formalin fixed, paraffin embedded tumor sections were stained with the monoclonal D5 antibody by avidin‐biotin complex immunohistochemistry. Results . Eighty‐eight (62%) of the 143 brain tumors showed positive ER‐D5 immunoreactivity. ER‐D5 expression was observed in 9/30 low grade astrocytomas, in 6/13 anaplastic astrocytomas, in 16/27 glioblastomas, in 2/5 ependymomas, in 5/8 medulloblastomas, in 10/15 meningiomas, in 20/23 schwannomas, in 11/11 hemangioblastomas, in 9/9 germ cell tumors, in 0/2 oligodendrogliomas, and in 17/28 pediatric and childhood brain tumors. The mean percentage of ER‐D5‐positive cells varied in different tumor types, was lowest in the meningotheliomatous meningiomas, and was highest in the hemangioblastomas. ER‐D5 immunoreactivity was also observed in the microvascular endothelial proliferations and in tumor blood vessels. ER‐D5 expression in tumors was not related to the overall tumor grades, but a statistically significant higher percentage of ER‐D5‐positive cells was noted in the glioblastomas compared with the low grade astrocytomas ( P < 0.05) and in the combined high grade tumors compared with the low grade tumors ( P < 0.005) if vascular‐origin tumor hemangioblastomas are considered a separate entity from other brain tumors. Conclusion . The current study suggests that the ER‐D5 antigen may participate in the growth of the intracranial tumors and tumor angiogenesis. ER‐D5 in embryonal and germ cell brain tumors suggests that ER‐D5 may be a developmentally regulated protein. Cancer 1995;75:2571‐8.